Table 3.
Treatment choice by site
| Intervention (21 clusters) | Usual care (25 clusters) | Overall (46 clusters) | P * | |
|---|---|---|---|---|
| Treatment decision-making: surgery versus primary endocrine thrapy | ||||
| All patients | 670 | 669 | 1339 | |
| Underwent consultation | 209 (31.2) | 240 (35.9) | 449 (33.5) | |
| Offered treatment choice | 168 (25.1) | 151 (22.6) | 319 (23.8) | |
| Treatment received | 0.009 | |||
| Surgery | 526 (78.5) | 547 (81.8) | 1073 (80.1) | |
| Primary endocrine therapy | 124 (18.5) | 89 (13.3) | 213 (15.9) | |
| Other/not treated | 20 (3.0) | 33 (4.9) | 53 (4.0) | |
| Patients with ER-positive disease | n = 591 | n = 570 | n = 1161 | |
| Underwent consultation | 197 (33.3) | 215 (37.7) | 412 (35.5) | |
| Offered treatment choice | 157 (26.6) | 140 (24.6) | 297 (25.6) | |
| Treatment received | 0.029 | |||
| Surgery | 451 (76.3) | 459 (80.5) | 910 (78.4) | |
| Primary endocrine therapy | 124 (21.0) | 88 (15.4) | 212 (18.3) | |
| Other/not treated | 16 (2.7) | 23 (4.0) | 39 (3.4) | |
| Treatment decision-making: chemotherapy after surgery | ||||
| All patients after surgery | n = 526 | n = 547 | n = 1073 | |
| Underwent consultation | 27 (5.1) | 67 (12.2) | 94 (8.8) | |
| Offered treatment choice | 21 (4.0) | 56 (10.2) | 77 97.2) | |
| Received chemotherapy | 69 (10.3) | 99 (14.8) | 168 (12.5) | 0.013 |
| High-risk patients | n = 267 | n = 310 | n = 577 | |
| Underwent consultation | 18 (6.7) | 61 (19.7) | 79 (13.7) | |
| Offered treatment choice | 17 (6.4) | 53 (17.1) | 70 (12.1) | |
| Received chemotherapy | 66 (24.7) | 92 (29.7) | 158 (27.4) | 0.183 |
Values in parentheses are percentages. ER, oestrogen receptor.
*Intraclass correlation coefficient: test.